TRIM25、RIG-Ⅰ在肝癌组织中的表达及其与患者预后的关系

Expressions of TRIM25 and RIG-Ⅰ in liver cancer tissues and their relationship with prognosis of patients

目的探讨TRIM25、RIG-Ⅰ在肝癌组织中的表达及二者与患者预后的关系。方法回顾性分析2017年1月至2018年1月南京医科大学附属淮安第一医院收治的82例肝癌患者资料,收集癌组织和癌旁组织(距肿瘤边缘>5 cm)标本。采用免疫组织化学法检测癌组织和癌旁组织TRIM25、RIG-Ⅰ蛋白表达情况。分析患者癌组织TRIM25、RIG-Ⅰ表达与临床病理特征的关系,采用Kaplan-Meier法分析癌组织TRIM25、RIG-Ⅰ不同表达状态患者总生存(OS)。结果癌组织TRIM25阳性率高于癌旁组织[68.29%(56/82)比21.95%(18/82),P<0.001],癌组织RIG-Ⅰ阳性率低于癌旁组织[31.71%(26/82)比74.39%(61/82),P<0.001]。低分化患者癌组织TRIM25阳性率高于高中分化患者(P<0.05),而RIG-Ⅰ阳性率低于高中分化患者(P<0.05);肝外转移患者癌组织TRIM25阳性率高于未肝外转移患者(P<0.05),而RIG-Ⅰ阳性率低于未肝外转移患者(P<0.05);临床分期Ⅲ~Ⅳ期患者癌组织TRIM25阳性率高于Ⅰ~Ⅱ期患者(P<0.05),而RIG-Ⅰ阳性率低于Ⅰ~Ⅱ期患者(P<0.05)。中位随访27个月(4~48个月),共2例患者失访;至2022年1月随访结束,全组生存率为43.75%(35/80),癌组织TRIM25阳性和阴性患者生存率分别33.33%(18/54)和65.38%(17/26),癌组织RIG-Ⅰ阳性和阴性患者生存率分别64.00%(16/25)和34.55%(19/55)。Kaplan-Meier法分析显示,癌组织TRIM25阴性患者OS优于阳性患者,癌组织RIG-Ⅰ阳性患者OS优于阴性患者,差异均有统计学意义(均P<0.05)。结论肝癌组织TRIM25表达升高,RIG-Ⅰ表达降低。肝癌组织TRIM25、RIG-Ⅰ表达与预后相关。

Objective To investigate the expressions of TRIM25 and RIG-Ⅰin liver cancer tissues and their relationship with the prognosis of patients.Methods The data of 82 patients with liver cancer who were admitted to the Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University from January 2017 to January 2018 were retrospectively analyzed,and their cancer tissue and paracancerous tissue(>5 cm from the edge of the tumor)specimens were collected.The protein expressions of TRIM25 and RIG-Ⅰin cancer tissues and paracancerous tissues were detected by immunohistochemistry.The relationship between TRIM25 and RIG-Ⅰexpressions in cancer tissues of patients and clinicopathological features was analyzed.Kaplan-Meier method was used to analyze the overall survival(OS)of patients with different TRIM25 and RIG-Ⅰexpression status.Results The positive rate of TRIM25 in cancer tissues was higher than that in paracancerous tissues[68.29%(56/82)vs.21.95%(18/82),P<0.001],and the positive rate of RIG-Ⅰin cancer tissues was lower than that in paracancerous tissues[31.71%(26/82)vs.74.39%(61/82),P<0.001].The positive rate of TRIM25 in cancer tissues of poorly differentiated patients was higher than that of highly and moderately differentiated patients(P<0.05),and the positive rate of RIG-Ⅰwas lower than that of highly and moderately differentiated patients(P<0.05).The positive rate of TRIM25 in cancer tissues of patients with extrahepatic metastasis was higher than that of patients without extrahepatic metastasis(P<0.05),but the positive rate of RIG-Ⅰwas lower than that of patients without extrahepatic metastasis(P<0.05).The positive rate of TRIM25 in patients with clinicalⅢ-Ⅳwas higher than that in patients with stageⅠ-Ⅱ(P<0.05),but the positive rate of RIG-Ⅰwas lower than that in patients with stageⅠ-Ⅱ(P<0.05).The median follow-up time was 27 months(4-48 months),2 patients were lost to follow-up.At the end of follow-up in January 2022,the overall survival rate was 43.75%(35/80).The survival rates of patients with TRIM25-positive and TRIM25-negative cancer tissues were 33.33%(18/54)and 65.38%(17/26),respectively.The survival rates of patients with RIG-Ⅰ-positive and RIG-Ⅰ-negative cancer tissues were 64.00%(16/25)and 34.55%(19/55),respectively.Kaplan-Meier analysis showed that the OS of patients with TRIM25-negative cancer tissues was better than that of patients with TRIM25-positive cancer tissues,and the OS of patients with RIG-Ⅰ-positive cancer tissues was better than that of patients with TRIM25-negative cancer tissues,and the differences were statistically significant(both P<0.05).Conclusions The expression of TRIM25 is increased and the expression of RIG-Ⅰis decreased in liver cancer tissues.The expressions of TRIM25 and RIG-Ⅰin liver cancer tissues are associated with prognosis.